Women’s Cancer and Cesium-131 Treatments: Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy

Jul 6, 2016

Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy

RICHLAND, Wash., July 6, 2016 /PRNewswire/ — IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced Jonathan Feddock M.D., Assistant Professor of Radiation Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, who discussed two presentations of gynecologic cancer patients who underwent treatment with permanent implantation of radiation therapy sources containing Cesium-131.

Dr. Feddock’s first presentation, titled: “Permanent Interstitial Re-Irradiation with Cesium-131: A Highly Successful Second Chance for Cure in Recurrent Pelvic Malignancies,” described 26 implants which were performed in 21 women who had experienced recurrent cancers of the uterus, cervix or vagina. These women had previously been treated with surgery and/or radiation. Historically, they would have been offered radical surgery with surgical removal of all pelvic organs. Of the 26 implants, 21 cancer sites remained visually free of cancer at a median of 14 months following Cesium-131 implantation, resulting in a local control rate of 80.7%. Local control in these cases was confirmed clinically.

Dr. Feddock commented: “These women were facing very radical surgery to address their recurrent cancers and it turned out that Cesium-131 therapy offered a much better solution for them. This is the first study utilizing Cesium-131 therapy for these gynecologic cancers and we have followed these women closely in order to evaluate the effectiveness of this treatment. We are very pleased with the results.”

During his second presentation, titled: “Outpatient Interstitial Implants–Integrating Cesium-131 Permanent Interstitial Brachytherapy into Definitive Treatment for Gynecologic Malignancies,” Dr. Feddock reported on a series of 22 women with pelvic cancer who underwent Cesium-131 implantation along with other forms of radiation therapy. The pelvic cancers in these patients were recently diagnosed and the patients had not yet undergone treatment. All these cancers were successfully controlled at a median follow-up of 16 months. Side effects were minor and all Cesium-131 treatments were performed as outpatient procedures.

Dr. Feddock stated: “The field of radiation oncology has long appreciated getting a high radiation dose to cancer. This fact is especially true for cancers that are bulky or have other features that put them at a higher risk of being left behind after surgery. By implanting Cesium-131 directly into these cancers we can boost the radiation dose in a way that results in local control with minimal side effects. The fact that we can perform this treatment without hospitalization and with local anesthetic gives these women a very convenient treatment that is highly successful.”

Tom LaVoy, CEO of IsoRay, Inc., stated, “We are encouraged by Dr. Feddock’s research in women’s cancers as Cesium-131 may provide effective treatments for women whose only alternative is highly invasive, life changing surgery. We look forward to Dr. Feddock’s ongoing research.”

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.

Safe Harbor Statement

Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether the GammaTile approach will be successful in future treatments, whether any future studies of the GammaTile approach will produce similar results to those reported in the presentation, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: IsoRay Medical, Info@Isoray.com, (509) 375-1202; Investors: Stephanie Prince, Managing Director, PCG Advisory, sprince@pcgadvisory.com, (646) 762-4518; Media: Sean Leous, Managing Director, PCG Advisory, sleous@pcgadvisory.com, (646) 863-8998

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
Schultz Public Relations
(302) 539-3747
schultzpr@mchsi.com